Publications:  Prof Chloe Orkin

Orkin C, DeJesus E, Sax PE, Arribas JR, Gupta SK, Martorell C, Stephens JL, Stellbrink HJ et al.(2020). Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir-containing regimens for initial treatment of HIV-1 infection: week 144 results from two randomised, double-blind, multicentre, phase 3, non-inferiority trials. The Lancet HIV vol. 7, (6) e389-e400.

Wan Y, Apea V, Dhairyawan R, Orkin C, Pearse RM, Prowle JR (2020). ETHICAL: Ethnic Disparities In COVID-19 Admissions in east London.

Stirrup OT, Asboe D, Pozniak A, Sabin CA, Gilson R, Mackie NE, Tostevin A, Hill T et al.(2020). Continuation of emtricitabine/lamivudine within combination antiretroviral therapy following detection of the M184V/I HIV-1 resistance mutation. HIV Medicine vol. 21, (5) 309-321.

Orkin C, Goddard SL(2020). Enrolling pregnant women with HIV into clinical trials. The Lancet HIV vol. 7, (5) e302-e303.

Orkin C, Eron JJ, Rockstroh J, Podzamczer D, Esser S, Vandekerckhove L, Van Landuyt E, Lathouwers E et al.(2020). Week 96 results of a phase 3 trial of darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-naive HIV-1 patients. AIDS (London, England) vol. 34, (5) 707-718.

Garvey LJ, Cooke GS, Smith C, Stingone C, Ghosh I, Dakshina S, Jain L, Waters LJ et al.(2020). Decline in Hepatitis C Virus (HCV) Incidence in Men Who Have Sex With Men Living With Human Immunodeficiency Virus: Progress to HCV Microelimination in the United Kingdom?. Clin Infect Dis

Thompson M, Orkin C, Molina JM, Sax P, Cahn P, Squires K, Xu X, Rodgers A et al.(2020). Once-daily doravirine for initial treatment of adults living with human immunodeficiency virus-1: An integrated safety analysis. Clinical Infectious Diseases vol. 70, (7) 1336-1343.

Orkin C, Molina JM, Lombaard J, Dejesus E, Rodgers A, Kumar S, Martin E, Hanna G et al.(2020). Once-daily doravirine in human immunodeficiency virus type 1-infected, antiretroviral-naive adults: An integrated efficacy analysis. Clinical Infectious Diseases vol. 70, (7) 1344-1352.

Orkin C, Arasteh K, Górgolas Hernández-Mora M, Pokrovsky V, Overton ET, Girard PM, Oka S, Walmsley S et al.(2020). Long-acting cabotegravir and rilpivirine after oral induction for HIV-1 infection. New England Journal of Medicine vol. 382, (12) 1124-1135.

Orkin C, Molina JM, Lombaard(2020). Erratum: Oncedaily doravirine in human immunodeficiency virus type 1-infected, antiretroviral-naive adults: An integrated efficacy analysis (Clinical Infectious Diseases DOI: 10.1093/cid/ciz424). Clinical Infectious Diseases vol. 70, (2)

Gupta N, Gilleece Y, Orkin C(2020). Implementing U=U in clinical practice: Results of a British HIV association members survey. Sexually Transmitted Infections

Cevik M, Orkin C(2019). Insights into HIV-1 capsid inhibitors in preclinical and early clinical development as antiretroviral agents. Expert Opinion on Investigational Drugs vol. 28, (12) 1021-1024.

Lampe FC, Rodger AJ, Burman W, Grulich A, Friedland G, Sadr WE, Neaton J, Corbelli GM et al.(2019). Impact of early antiretroviral treatment on sexual behaviour: A randomised comparison. AIDS vol. 33, (15) 2337-2350.

Lampe FC, Rodger AJ, Burman W, Grulich A, Friedland G, Sadr WE, Neaton J, Corbelli GM et al.(2019). Impact of early antiretroviral treatment on sexual behaviour: a randomised comparison. AIDS vol. 33, (15) 2337-2350.

Martin EA, Hwang C, Orkin C(2019). Reply to Lanzafame et al. Clinical Infectious Diseases vol. 69, (10) 1832-1833.

Quercia R, Orkin C, D'Amico R, Mrus J, Wu S, Cutrell A, Chow K, Polli J et al. (2019). EACS 2019-Abstract Book. HIV MEDICINE. vol. 20, 3-3.

Orkin C, Elion R, Thompson M, Rockstroh J, Xu ZJ, Martin EA, Hwang C, Sklar P et al. (2019). Effect of doravirine on body weight and body mass index in treatment naive adults with HIV-1. HIV MEDICINE. vol. 20, 7-8.

Orkin C, Kityo C, Koenig E, Natukunda E, Ajana F, Gandhi-Patel B, Liu Y, Wei L et al. (2019). Efficacy and safety of bictegravir/emtricitabine/tenofovir alafenamide vs comparators in cis-women and girls (living with HIV): an analysis of 5 clinical trials. HIV MEDICINE. vol. 20, 22-22.

Orkin C, Sax PE, Arribas J, Gupta S, Martorell C, Stephens JL, Stellbrink H-J, Dejesus E et al. (2019). Long-term efficacy and safety of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in ART-naive adults. HIV MEDICINE. vol. 20, 94-95.

Stellbrink H-J, Post FA, Podzamczer D, Arribas J, Cua E, Molina J-M, Orkin C, Rockstroh JK et al. (2019). Safety and efficacy of switching from tenofovir disoproxil fumarate to tenofovir alafenamide in people with HIV aged 50 years and older. HIV MEDICINE. vol. 20, 138-138.

Sax PE, Erlandson KM, Lake JE, McComsey GA, Orkin C, Esser S, Brown TT, Rockstroh JK et al.(2019). Weight Gain Following Initiation of Antiretroviral Therapy: Risk Factors in Randomized Comparative Clinical Trials. Clin Infect Dis

Eron JJ, Orkin C, Cunningham D, Pulido F, Post FA, De Wit S, Lathouwers E, Hufkens V et al.(2019). Week 96 efficacy and safety results of the phase 3, randomized EMERALD trial to evaluate switching from boosted-protease inhibitors plus emtricitabine/tenofovir disoproxil fumarate regimens to the once daily, single-tablet regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in treatment-experienced, virologically-suppressed adults living with HIV-1. Antiviral Research vol. 170,

Mbisa JL, Kirwan P, Tostevin A, Ledesma J, Bibby DF, Brown A, Myers R, Hassan AS et al.(2019). Determining the Origins of Human Immunodeficiency Virus Type 1 Drug-resistant Minority Variants in People Who Are Recently Infected Using Phylogenetic Reconstruction. Clin Infect Dis vol. 69, (7) 1136-1143.

Aboud M, Orkin C, Podzamczer D, Bogner JR, Baker D, Khuong-Josses MA, Parks D, Angelis K et al.(2019). Efficacy and safety of dolutegravir–rilpivirine for maintenance of virological suppression in adults with HIV-1: 100-week data from the randomised, open-label, phase 3 SWORD-1 and SWORD-2 studies. The Lancet HIV vol. 6, (9) e576-e587.

Huhn GD, Eron JJ, Girard PM, Orkin C, Molina JM, Dejesus E, Petrovic R, Luo D et al.(2019). Darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-experienced, virologically suppressed patients with HIV-1: Subgroup analyses of the phase 3 EMERALD study. AIDS Research and Therapy vol. 16, (1)

Gupta SK, Post FA, Arribas JR, Eron JJ, Wohl DA, Clarke AE, Sax PE, Stellbrink HJ et al.(2019). Renal safety of tenofovir alafenamide vs. tenofovir disoproxil fumarate: A pooled analysis of 26 clinical trials. AIDS vol. 33, (9) 1455-1465.

Bundle N, Balasegaram S, Parry S, Ullah S, Harris RJ, Ahmad K, Foster GR, Tong CYW et al.(2019). Seroprevalence and demographic factors associated with hepatitis B, hepatitis C and HIV infection from a hospital emergency department testing programme, London, United Kingdom, 2015 to 2016. Eurosurveillance vol. 24, (27)

Orkin C(2019). Does less equal more yet?. The Lancet HIV vol. 6, (7) e412-e413.

Cullen L, Grenfell P, Rodger A, Orkin C, Mandal S, Rhodes T(2019). 'Just another vial': A qualitative study to explore the acceptability and feasibility of routine blood-borne virus testing in an emergency department setting in the UK. BMJ Open vol. 9, (4)

Podzamczer D, Stellbrink H-J, Orkin C, Pozniak A, Arribas J, Koenig E, Ramgopal M, Baumgarten A et al. (2019). B/F/TAF versus ABC/DTG/3TC or DTG + F/TAF in treatment-naive adults with high baseline viral load or low baseline CD4 cell count: week 96 results. HIV MEDICINE. vol. 20, 18-18.

Van Wyk J, Orkin C, Rubio-Garcia R, Bogner J, Baker D, Khuong-Josses M-A, Parks D, Angelis K et al. (2019). Durable suppression and low rate of virological failures 3 years after switch to DTG plus RPV two-drug regimen: SWORD 1 and 2 studies. HIV MEDICINE. vol. 20, 18-19.

Amele S, Peters L, Sluzhynska M, Yakovlev A, Scherrer A, Domingo P, Gerstoft J, Viard JP et al.(2019). Establishing a hepatitis C continuum of care among HIV/hepatitis C virus-coinfected individuals in EuroSIDA. HIV Medicine vol. 20, (4) 264-273.

Orkin C, Arasteh K, Hernandez-Mora MG, Pokrovsky V, Overton ET, Girard P-M, Oka S, D'Amico R et al. (2019). Long-active cabotegravir plus rilpivirine for HIV maintenance: FLAIR week-48 results. HIV MEDICINE. vol. 20, 6-7.

Martinello M, Orkin C, Cooke G, Bhagani S, Gane E, Kulasegaram R, Shaw D, Tu E et al. (2019). Shortened duration pan-genotypic therapy with glecaprevir-pibrentasvir for six weeks among people with acute and recent HCV infection. JOURNAL OF HEPATOLOGY. vol. 70, E231-E231.

Orkin C, Squires KE, Molina JM, Sax PE, Wong WW, Sussmann O, Kaplan R, Lupinacci L et al.(2019). Doravirine/Lamivudine/Tenofovir disoproxil fumarate is non-inferior to efavirenz/emtricitabine/tenofovir disoproxil fumarate in treatment-naive adults with human immunodeficiency virus-1 infection: Week 48 results of the DRIVE-AHEAD Trial. Clinical Infectious Diseases vol. 68, (4) 535-544.

Finnerty F, Azad Y, Orkin C(2019). Hostile health-care environment could increase migrants' risk of HIV and prevent access to vital services. The Lancet HIV vol. 6, (2)

Gatell JM, Assoumou L, Moyle G, Waters L, Johnson M, Domingo P, Fox J, Martinez E et al.(2019). Immediate versus deferred switching from a boosted protease inhibitor-based regimen to a dolutegravir-based regimen in virologically suppressed patients with high cardiovascular risk or age ≥50 years: Final 96-week results of the NEAT022 study. Clinical Infectious Diseases vol. 68, (4) 597-606.

Cahn P, Madero JS, Arribas JR, Antinori A, Ortiz R, Clarke AE, Hung CC, Rockstroh JK et al.(2019). Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials. The Lancet vol. 393, (10167) 143-155.

Martinello M, Orkin C, Cooke G, Bhagani S, Gane E, Kulasegaram R, Shaw D, Tu E et al.(2019). Short-Duration Pan-Genotypic Therapy With Glecaprevir/Pibrentasvir for 6 Weeks Among People With Recent Hepatitis C Viral Infection. Hepatology

Geretti AM, White E, Orkin C, Tostevin A, Tilston P, Chadwick D, Leen C, Sabin C et al.(2019). Virological outcomes of boosted protease inhibitor-based first-line ART in subjects harbouring thymidine analogue-associated mutations as the sole form of transmitted drug resistance. Journal of Antimicrobial Chemotherapy vol. 74, (3) 746-753.

Hagins D, Orkin C, Daar ES, Mills A, Brinson C, DeJesus E, Post FA, Morales-Ramirez J et al.(2018). Switching to coformulated rilpivirine (RPV), emtricitabine (FTC) and tenofovir alafenamide from either RPV, FTC and tenofovir disoproxil fumarate (TDF) or efavirenz, FTC and TDF: 96-week results from two randomized clinical trials. HIV Medicine vol. 19, (10) 724-733.

Podzamczer D, Stellbrink H, Orkin C, Pozniak A, Arribas J, Koenig E, Ramgopal M, Baumgarten A et al. (2018). B/F/TAF versus ABC/DTG/3TC or DTG + F/TAF in treatment-naive adults with high baseline viral load or low baseline CD4 count in two Phase III randomized, controlled clinical trials: Week 96 results. JOURNAL OF THE INTERNATIONAL AIDS SOCIETY. vol. 21,

Orkin C, Eron J, Rockstroh J, Podzamczer D, Esser S, Vandekerckhove L, Van Landuyt E, Lathouwers E et al. (2018). Efficacy and safety of the once-daily, darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) single-tablet regimen (STR) in ART-naive, HIV-1-infected adults: AMBER Week 96 results. JOURNAL OF THE INTERNATIONAL AIDS SOCIETY. vol. 21,

Orkin C, Lampe F, Izambert C, Waters L (2018). Mental health and HIV: what we all need to know. JOURNAL OF THE INTERNATIONAL AIDS SOCIETY. vol. 21,

Martinello M, Bhagani S, Gane E, Orkin C, Cooke G, Dore GJ, Petoumenos K, Applegate TL et al.(2018). Shortened therapy of eight weeks with paritaprevir/ritonavir/ombitasvir and dasabuvir is highly effective in people with recent HCV genotype 1 infection. Journal of Viral Hepatitis vol. 25, (10) 1180-1188.

Orkin C, Porteiro N, Berhe M, Dretler R, Viciana P, Tseng Y, Oprea C, Johnson M et al. (2018). Two-drug regimen of dolutegravir plus lamivudine (DTG+3TC) is non-inferior to dolutegravir plus tenofovir/emtricitabine (DTG plus TDF/FTC) at 48 weeks in antiretroviral treatment-naive adults with HIV-1 infection: subgroup analyses in the GEMINI studies. JOURNAL OF THE INTERNATIONAL AIDS SOCIETY. vol. 21,

Rockstroh JK, Lacombe K, Viani RM, Orkin C, Wyles D, Luetkemeyer AF, Soto-Malave R, Flisiak R et al.(2018). Efficacy and Safety of Glecaprevir/Pibrentasvir in Patients Coinfected with Hepatitis C Virus and Human Immunodeficiency Virus Type 1: The EXPEDITION-2 Study. Clinical Infectious Diseases vol. 67, (7) 1010-1017.

Cresswell FV, Ellis J, Hartley J, Sabin CA, Orkin C, Churchill DR(2018). A systematic review of risk of HIV transmission through biting or spitting: implications for policy. HIV Medicine vol. 19, (8) 532-540.

Eron JJ, Orkin C, Gallant J, Molina JM, Negredo E, Antinori A, Mills A, Reynes J et al.(2018). A week-48 randomized phase-3 trial of darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-naive HIV-1 patients. AIDS vol. 32, (11) 1431-1442.

Cevik M, Orkin C(2018). Fixed dose darunavir boosted with cobicistat combined with emtricitabine and tenofovir alafenamide fumarate. Current Opinion in HIV and AIDS vol. 13, (4) 315-319.

Psomas C, Kinloch S, Sabin C, Soriano V, Solas C, Orkin C, Bernardino J, Curran A et al.(2018). Highlights from the 20th International Symposium on HIV and Emerging Infectious Diseases (ISHEID) 16-18 May 2018, Marseille, France: from HIV and comorbidities to global health. J Virus Erad vol. 4, (3) 196-207.

Jose S, Delpech V, Howarth A, Burns F, Hill T, Porter K, Sabin CA, Ainsworth J et al.(2018). A continuum of HIV care describing mortality and loss to follow-up: a longitudinal cohort study. The Lancet HIV vol. 5, (6) e301-e308.

Parry S, Bundle N, Ullah S, Foster GR, Ahmad K, Tong CYW, Balasegaram S, Orkin C(2018). Implementing routine blood-borne virus testing for HCV, HBV and HIV at a London Emergency Department-uncovering the iceberg?. Epidemiology and Infection vol. 146, (8) 1026-1035.

Santos JR, Cozzi-Lepri A, Phillips A, De Wit S, Pedersen C, Reiss P, Blaxhult A, Lazzarin A et al.(2018). Long-term effectiveness of recommended boosted protease inhibitor-based antiretroviral therapy in Europe. HIV Medicine vol. 19, (5) 324-338.

Volz EM, Le Vu S, Ratmann O, Tostevin A, Dunn D, Orkin C, O'Shea S, Delpech V et al.(2018). Molecular Epidemiology of HIV-1 Subtype B Reveals Heterogeneous Transmission Risk: Implications for Intervention and Control. Journal of Infectious Diseases vol. 217, (10) 1522-1529.

Stirrup OT, Dunn DT, Tostevin A, Sabin CA, Pozniak A, Asboe D, Cox A, Orkin C et al.(2018). Risk factors and outcomes for the Q151M and T69 insertion HIV-1 resistance mutations in historic UK data. AIDS Research and Therapy vol. 15, (1)

Cresswell F, Ellis J, Hartley J, Sabin C, Brook G, Orkin C, Churchill D (2018). A systematic review of risk of HIV transmission through biting or spitting: implications for policy. HIV MEDICINE. vol. 19, S43-S43.

Roen A, Laut K, Pelchen-Matthews A, Borodulina E, Caldeira L, Clarke A, Clotet B, d'Arminio Monforte A et al.(2018). Abacavir usage patterns and hypersensitivity reactions in the EuroSIDA cohort. HIV Medicine vol. 19, (4) 252-260.

Orkin C, Libre J, Kahl L, Blair E, Wynne B, Curtis L, Angelis K, Shah R et al. (2018). Renal, Inflammatory and bone biomarkers following switch to the DTG + RPV 2-drug regimen: the SWORD-1 and SWORD-2 studies. HIV MEDICINE. vol. 19, S17-S17.

Orkin C, Khuong-Josses M-A, Lutz T, Baker D, Rubio R, Blair E, Kahl L, Angelis K et al. (2018). Safety and efficacy of DTG plus RPV in the phase III SWORD-1 and SWORD-2 studies: 48-week subgroup analysis by baseline third agent class and geographic location. HIV MEDICINE. vol. 19, S28-S29.

Cozzi-Lepri A, Zangerle R, Machala L, Zilmer K, Ristola M, Pradier C, Kirk O, Sambatakou H et al.(2018). Incidence of cancer and overall risk of mortality in individuals treated with raltegravir-based and non-raltegravir-based combination antiretroviral therapy regimens. HIV Medicine vol. 19, (2) 102-117.

Shepherd L, Borges H, Harvey R, Bower M, Grulich A, Silverberg M, Weber J, Ristola M et al.(2018). The extent of B-cell activation and dysfunction preceding lymphoma development in HIV-positive people. HIV Medicine vol. 19, (2) 90-101.

Jose S, Hamzah L, Jones R, Williams D, Winston A, Burns F, Phillips AN, Sabin CA et al.(2018). Chronic kidney disease risk in African and Caribbean populations with HIV. Journal of Infectious Diseases vol. 218, (11) 1767-1772.

Orkin C, Molina JM, Negredo E, Arribas JR, Gathe J, Eron JJ, Van Landuyt E, Lathouwers E et al.(2018). Efficacy and safety of switching from boosted protease inhibitors plus emtricitabine and tenofovir disoproxil fumarate regimens to single-tablet darunavir, cobicistat, emtricitabine, and tenofovir alafenamide at 48 weeks in adults with virologically suppressed HIV-1 (EMERALD): a phase 3, randomised, non-inferiority trial. The Lancet HIV vol. 5, (1) e23-e34.

Orkin C, Llibre JM, Gallien S, Antinori A, Behrens GMN, Carr A(2018). Nucleoside reverse transcriptase inhibitor-reducing strategies in HIV treatment: assessing the evidence. HIV Medicine vol. 19, (1) 18-32.

Peters L, Mocroft A, Grint D, Moreno S, Calmy A, Jevtovic D, Sambatakou H, Lacombe K et al.(2018). Uptake of tenofovir-based antiretroviral therapy among HIV-HBV-coinfected patients in the EuroSIDA study. Antiviral Therapy vol. 23, (5) 405-413.

Orrell C, Hagins DP, Belonosova E, Porteiro N, Walmsley S, Falcó V, Man CY, Aylott A et al.(2017). Fixed-dose combination dolutegravir, abacavir, and lamivudine versus ritonavir-boosted atazanavir plus tenofovir disoproxil fumarate and emtricitabine in previously untreated women with HIV-1 infection (ARIA): week 48 results from a randomised, open-label, non-inferiority, phase 3b study. The Lancet HIV vol. 4, (12) e536-e546.

Gallant J, Lazzarin A, Mills A, Orkin C, Podzamczer D, Tebas P, Girard PM, Brar I et al.(2017). Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial. The Lancet vol. 390, (10107) 2063-2072.

Patterson S, Jose S, Samji H, Cescon A, Ding E, Zhu J, Anderson J, Burchell AN et al.(2017). A tale of two countries: all-cause mortality among people living with HIV and receiving combination antiretroviral therapy in the UK and Canada. HIV Medicine vol. 18, (9) 655-666.

Martinello M, Bhagani S, Gane EJ, Orkin C, Cooke G, Kulasegaram R, Shaw D, Hellard M et al. (2017). Shortened therapy of 8 weeks duration with paritaprevir/ritonavir/ombitasvir and dasabuvir is highly effective in people with acute and recent genotype 1 HCV infection: The TARGET3D Study. HEPATOLOGY. vol. 66, 574A-575A.

Gourlay A, Fox J, Gafos M, Fidler S, Nwokolo N, Clarke A, Gilson R, Orkin C et al.(2017). A qualitative study exploring the social and environmental context of recently acquired HIV infection among men who have sex with men in South-East England. BMJ Open vol. 7, (8)

Pasvol TJ, Orkin C(2017). Few men who have sex with men (MSM) attending two inner-city clinics were tested for hepatitis C virus (HCV) despite high risk: A retrospective analysis of sexual health screening in East London. Sexually Transmitted Infections vol. 93, (5)

Gallant J, Lazzarin A, Mills A, Orkin C, Podzamczer D, Tebas P, Girard P-M, Brar I et al. (2017). A Phase 3 randomized controlled clinical trial of bictegravir in a fixed dose combination, B/F/TAF, vs ABC/DTG/3TC in treatment-naive adults at Week 48. JOURNAL OF THE INTERNATIONAL AIDS SOCIETY. vol. 20, 103-104.

Smit E, White E, Clark D, Churchill D, Zhang H, Collins S, Pillay D, Sabin C et al.(2017). An association between K65R and HIV-1 subtype C viruses in patients treated with multiple NRTIs. Journal of Antimicrobial Chemotherapy vol. 72, (7) 2075-2082.

O'Connor J, Smith C, Lampe FC, Johnson MA, Chadwick DR, Nelson M, Dunn D, Winston A et al.(2017). Durability of viral suppression with first-line antiretroviral therapy in patients with HIV in the UK: an observational cohort study. The Lancet HIV vol. 4, (7) e295-e302.

Raffi F, Orkin C, Clarke A, Slama L, Gallant J, Daar E, Henry K, Santana-Bagur J et al. (2017). Brief Report: Long-Term (96-Week) Efficacy and Safety after Switching from Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in HIV-Infected, Virologically Suppressed Adults. Journal of Acquired Immune Deficiency Syndromes. vol. 75, 226-231.

Borges ÁH, Hoy J, Florence E, Sedlacek D, Stellbrink HJ, Uzdaviniene V, Tomazic J, Gargalianos-Kakolyris P et al.(2017). Antiretrovirals, Fractures, and Osteonecrosis in a Large International HIV Cohort. Clinical Infectious Diseases vol. 64, (10) 1413-1421.

Orkin C, DeJesus E, Ramgopal M, Crofoot G, Ruane P, LaMarca A, Mills A, Vandercam B et al.(2017). Switching from tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority study. The Lancet HIV vol. 4, (5) e195-e204.

Howarth AR, Burns FM, Apea V, Jose S, Hill T, Delpech VC, Evans A, Mercer CH et al.(2017). Development and application of a new measure of engagement in out-patient HIV care. HIV Medicine vol. 18, (4) 267-274.

McNulty M, Orkin C, Smith C, Marshall N, Swaden L, Burns F (2017). Real-life experience of switching to protease inhibitor-based dual antiretroviral therapy (PIDAT). HIV MEDICINE. vol. 18, 17-18.

Orkin C, DeJesus E, Ramgopal M, Crofoot G, Ruane P, LaMarca A, Mills A, Van der Cam B et al. (2017). Switching from efavirenz/emtricitabine/tenofovir (EFV/FTC/TDF) or rilpivirine/emtricitabine/tenofovir disoproxil fumarate (RPV/FTC/TDF) to rilpivirine/emtricitabine/tenofovir alafenamide (RPV/FTC/TAF): safety and efficacy through 48 weeks. HIV MEDICINE. vol. 18, 21-21.

Tostevin A, White E, Dunn D, Croxford S, Delpech V, Williams I, Asboe D, Pozniak A et al.(2017). Recent trends and patterns in HIV-1 transmitted drug resistance in the United Kingdom. HIV Medicine vol. 18, (3) 204-213.

Stöhr W, Dunn DT, Arenas-Pinto A, Orkin C, Clarke A, Williams I, Johnsone M, Beeching NJ et al.(2016). Factors associated with virological rebound in HIV-infected patients receiving protease inhibitor monotherapy. AIDS vol. 30, (17) 2617-2624.

Dhairyawan R, O'Connell R, Flanagan S, Wallis E, Orkin C(2016). Linkage to care after routine HIV, hepatitis B & C testing in the emergency department: The 'Going Viral' campaign. Sexually Transmitted Infections vol. 92, (7)

Barr E, Rockstroh JK, Nelson M, Katlama C, Lalezari J, Mallolas J, Bloch M, Matthews G et al. (2016). High efficacy of elbasvir/grazoprevir (EBR/GZR) in HCV genotype 1, 4, and 6-infected patients with HIV coinfection: SVR24 data from the phase 3 C-EDGE Coinfection study. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY. vol. 31, 66-66.

Raffi F, Orkin C, Clarke A, Slama L, Gallant J, Daar E, Yan M, Abram ME et al. (2016). Long-term (96-week) efficacy and safety after switching from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF) in HIV-infected, virologically suppressed adults. JOURNAL OF THE INTERNATIONAL AIDS SOCIETY. vol. 19,

Marshall N, McNulty M, Smith C, Swaden L, Burns F, Orkin C (2016). Real-life experience of switching to protease inhibitor-based dual antiretroviral therapy (PIDAT). JOURNAL OF THE INTERNATIONAL AIDS SOCIETY. vol. 19,

Orkin C, DeJesus E, Ramgopal M, Crofoot G, Ruane P, LaMarca A, Mills A, Van der Cam B et al. (2016). Switching from rilpivirine/emtricitabine/tenofovir disoproxil fumarate (RPV/FTC/TDF) to rilpivirine/ emtricitabine/tenofovir alafenamide (RPV/FTC/TAF): safety and efficacy through 48 weeks. JOURNAL OF THE INTERNATIONAL AIDS SOCIETY. vol. 19,

Shepherd L, Borges H, Ledergerber B, Domingo P, Castagna A, Rockstroh J, Knysz B, Tomazic J et al.(2016). Infection-related and -unrelated malignancies, HIV and the aging population. HIV Medicine vol. 17, (8) 590-600.

Churchill D, Waters L, Ahmed N, Angus B, Boffito M, Bower M, Dunn D, Edwards S et al.(2016). British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2015. HIV Medicine vol. 17, s2-s104.

Hughes RA, Sterne JAC, Walsh J, Post F, Nelson M, Jose S, Hill T, Tilling K et al.(2016). Predicting virological decay in patients starting combination antiretroviral therapy. AIDS vol. 30, (11) 1817-1827.

Rodger A, Lampe F, Burman W, Gruhlich A, Friedland G, El-Sadr W, Neaton J, Emery S et al. (2016). Assessment of the impact of early ART on sexual behaviour in INSIGHT strategic timing of antiretroviral treatment (START) trial. JOURNAL OF THE INTERNATIONAL AIDS SOCIETY. vol. 19,

Orkin C, Jeffery-Smith A, Foster GR, Tong CYW(2016). Retrospective hepatitis C seroprevalence screening in the antenatal setting—should we be screening antenatal women?. BMJ Open vol. 6, (5) e010661-e010661.

Bath R, O'Connell R, Lascar M, Ferrand R, Strachan S, Matin N, Bassnet I, Orkin C(2016). TestMeEast: A campaign to increase HIV testing in hospitals and to reduce late diagnosis. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV vol. 28, (5) 608-611.

Jose S, Quinn K, Dunn D, Cox A, Sabin C, Fidler S, Fisher M, Gazzard B et al.(2016). Virological failure and development of new resistance mutations according to CD4 count at combination antiretroviral therapy initiation. HIV Medicine vol. 17, (5) 368-372.

Umaipalan A, Jayakumar A, Patel M, Wallis E, Baily G, Orkin C (2016). Early virological response did not predict high levels of sustained virological response at 12 weeks (SVR12) in HIV/HCV-co-infected patients treated with directly acting agent (DAA)-containing therapy. HIV MEDICINE. vol. 17, 45-45.

Stohr W, Dunn D, Arenas-Pinto A, Paton N, Orkin C, Clarke A, Williams I, Johnson M et al. (2016). Factors associated with virological rebound in patients receiving protease inhibitor monotherapy in the PIVOT trial. HIV MEDICINE. vol. 17, 11-11.

Orkin C, Clarke A, Gallant J, Daar E, Raffi F, Antonucci S, Mingjin Y, Chang A et al. (2016). Switching tenofovir disoproxil fumarate to tenofovir alafenamide in virologically suppressed adults. HIV MEDICINE. vol. 17, 18-18.

Orkin C, Flanagan S, Wallis E, Ireland G, Dhairyawan R, Fox J, Nandwani R, O'Connell R et al.(2016). Incorporating HIV/hepatitis B virus/hepatitis C virus combined testing into routine blood tests in nine UK Emergency Departments: The "Going Viral" campaign. HIV Medicine vol. 17, (3) 222-230.

Booth JW, Hamzah L, Jose S, Horsfield C, O'Donnell P, McAdoo S, Kumar EA, Turner-Stokes T et al.(2016). Clinical characteristics and outcomes of HIV-associated immune complex kidney disease. Nephrology Dialysis Transplantation vol. 31, (12) 2099-2107.

Cain LE, Caniglia EC, Phillips A, Olson A, Muga R, Pérez-Hoyos S, Abgrall S, Costagliola D et al.(2016). Efavirenz versus boosted atazanavir-containing regimens and immunologic, virologic, and clinical outcomes: A prospective study of HIV-positive individuals. Medicine (United States) vol. 95, (41)

Williams AJ, Wallis E, Orkin C(2016). HIV research trials versus standard clinics for antiretroviral-naïve patients: the outcomes differ but do the patients?. International Journal of STD and AIDS vol. 27, (7) 537-542.

El Bouzidi K, White E, Mbisa JL, Sabin CA, Phillips AN, Mackie N, Pozniak AL, Tostevin A et al.(2016). HIV-1 drug resistance mutations emerging on darunavir therapy in PI-naive and -experienced patients in the UK. Journal of Antimicrobial Chemotherapy vol. 71, (12) 3487-3494.

Llibre JM, Cozzi-Lepri A, Pedersen C, Ristola M, Losso M, Mocroft A, Mitsura V, Falconer K et al.(2016). Long-term effectiveness of unboosted atazanavir plus abacavir/lamivudine in subjects with virological suppression: A prospective cohort study. Medicine (United States) vol. 95, (40)

Mills A, Arribas JR, Andrade-Villanueva J, DiPerri G, Van Lunzen J, Koenig E, Elion R, Cavassini M et al.(2016). Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised, active-controlled, multicentre, open-label, phase 3, non-inferiority study. The Lancet Infectious Diseases vol. 16, (1) 43-52.

Orkin C, Wallis E(2015). Should HIV testing week be blood-borne-virus testing week?. The Lancet HIV vol. 2, (12) e510-e511.

Huntington S, Thorne C, Newell ML, Anderson J, Taylor GP, Pillay D, Hill T, Tookey PA et al.(2015). The risk of viral rebound in the year after delivery in women remaining on antiretroviral therapy. AIDS vol. 29, (17) 2269-2278.

Murray DD, Suzuki K, Law M, Trebicka J, Neuhaus J, Wentworth D, Johnson M, Vjecha MJ et al.(2015). Circulating microRNAs in sera correlate with soluble biomarkers of immune activation but do not predict mortality in ART treated individuals with HIV-1 infection: A case control study. PLoS ONE vol. 10, (10)

Podlekareva D, Grint D, Karpov I, Vassilenko A, Rakmanova A, Mansinho K, Chentsova N, Kravchenko E et al.(2015). Changing utilization of Stavudine (d4T) in HIV-positive people in 2006-2013 in the EuroSIDA study. HIV Medicine vol. 16, (9) 533-543.

Paton NI, Stöhr W, Arenas-Pinto A, Fisher M, Williams I, Johnson M, Orkin C, Chen F et al.(2015). Protease inhibitor monotherapy for long-term management of HIV infection: A randomised, controlled, open-label, non-inferiority trial. The Lancet HIV vol. 2, (10) e417-e426.

Rockstroh JK, Nelson M, Katlama C, Lalezari J, Mallolas J, Bloch M, Matthews GV, Saag MS et al.(2015). Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): A non-randomised, open-label trial. The Lancet HIV vol. 2, (8) e319-e327.

Hoehn KB, Gall A, Bashford-Rogers R, Fidler SJ, Kaye S, Weber JN, McClure MO, Kellam P et al.(2015). Dynamics of immunoglobulin sequence diversity in HIV-1 infected individuals. Philosophical Transactions of the Royal Society B: Biological Sciences vol. 370, (1676)

Thornhill J, Sivaramakrishnan A, Orkin C(2015). Pneumococcal vaccination in people living with HIV. Vaccine vol. 33, (28) 3159-3160.

Huntington S, Thorne C, Newell ML, Anderson J, Taylor GP, Pillay D, Hill T, Tookey PA et al.(2015). Pregnancy is associated with elevation of liver enzymes in HIV-positive women on antiretroviral therapy. AIDS vol. 29, (7) 801-809.

Deayton J, O'Sullivan E, McKnight A, Groves K, Bibby D, Clark D, Orkin C, Reeves I et al.(2015). Disease progression in HIV-1 controllers; uptake and outcome of antiretroviral therapy. HIV MEDICINE vol. 16, 20-20.

Wallis E, Umaipalan A, Flanagan S, Montoto S, Orkin C(2015). Post chemotherapy liver dysfunction and reactivation of Hepatitis B (HBV) and C (HCV) in an HIV-infected cohort. HIV MEDICINE vol. 16, 41-41.

Orkin C, Leach E, Flanagan S, Wallis E, Foster GR, Ruf M, Tong CY (2015). UNEXPECTED HIGH PREVALENCE OF HCV-VIRAEMIA (HCV RNA plus ) IN THE EMERGENCY DEPARTMENT (ED) OF A LONDON HOSPITAL - SHOULD WE BE SCREENING FOR HCV IN ED ATTENDEES?. JOURNAL OF HEPATOLOGY. vol. 62, S825-S825.

Mocroft A, Lundgren JD, Ross M, Law M, Reiss P, Kirk O, Smith C, Wentworth D et al.(2015). Development and Validation of a Risk Score for Chronic Kidney Disease in HIV Infection Using Prospective Cohort Data from the D:A:D Study. PLoS Medicine vol. 12, (3)

ORKIN C, LEACH E, FLANAGAN S, WALLIS E, RUF M, FOSTER GR, TONG CYW(2015). High prevalence of hepatitis C (HCV) in the emergency department (ED) of a London hospital: should we be screening for HCV in ED attendees?. Epidemiology and Infection

Moyle GJ, Orkin C, Fisher M, Dhar J, Anderson J, Wilkins E, Ewan J, Ebrahimi R et al.(2015). A randomized comparative trial of continued abacavir/lamivudine plus efavirenz or replacement with efavirenz/emtricitabine/tenofovir DF in hypercholesterolemic HIV-1 infected individuals. PLoS ONE vol. 10, (2)

Orkin C, Leach E, Flanagan S, Wallis E, Ruf M, Foster GR, Tong CYW(2015). High prevalence of hepatitis C (HCV) in the emergency department (ED) of a London hospital: Should we be screening for HCV in ED attendees?. Epidemiology and Infection vol. 143, (13) 2837-2840.

Wallis E, Thornhill J, Saunders J, Orkin C(2015). Introducing opt-out HIV testing in an acute medical admissions unit: Does it improve testing uptake in those with lobar pneumonia?. Sexually Transmitted Infections vol. 91, (3)

Grint D, Peters L, Rockstroh JK, Rakmanova A, Trofimova T, Lacombe K, Karpov I, Galli M et al.(2015). Liver-related death among HIV/hepatitis C virus-co-infected individuals: Implications for the era of directly acting antivirals. AIDS vol. 29, (10) 1205-1215.

Orkin C, Umaipalan A(2015). NtRTI sparing in patients at risk of bone disease. The Lancet HIV vol. 2, (11) e452-e453.

Bath R, Ahmad K, Orkin C(2015). Routine HIV testing within the emergency department of a major trauma centre: A pilot study. HIV Medicine vol. 16, (5) 326-328.

Younossi ZM, Stepanova M, Sulkowski M, Naggie S, Puoti M, Orkin C, Hunt SL (2015). Sofosbuvir and Ribavirin for Treatment of Chronic Hepatitis C in Patients Coinfected with Hepatitis C Virus and HIV: The Impact on Patient-Reported Outcomes. Journal of Infectious Diseases. vol. 212, 367-377.

Molina JM, Orkin C, Iser DM, Zamora FX, Nelson M, Stephan C, Massetto B, Gaggar A et al.(2015). Sofosbuvir plus ribavirin for treatment of hepatitis C virus in patients co-infected with HIV (PHOTON-2): A multicentre, open-label, non-randomised, phase 3 study. The Lancet vol. 385, (9973) 1098-1106.

Krupiczojc M, Goldsmith P, Cerio R, Orkin C, Williams E, Harwood C (2014). Noduloulcerative skin lesions in an HIV-positive man: an increasingly common presentation of an ancient disease. BRITISH JOURNAL OF DERMATOLOGY. vol. 171, 101-102.

Bath R, O'Connell R, Lascar M, Ferrand R, Matin N, Basnett I, Apea V, Phiri E et al. (2014). #TestMeEast@EuroHIVTestingWeek: a celebrity-endorsed, newsworthy NHS campaign across six hospitals to test 2500 patients (500/day) based in outpatients (OPD) and emergency departments (ED): the results. HIV MEDICINE. vol. 15, 95-95.

Wikeley S, Bradbury R, Bath R, O'Connell R, Matin N, Saunders J, Lascar M, Phiri E et al. (2014). 'Legion' of medical students participates in largest hospital-based HIV testing week initiative - breaking down testing barriers in the doctors of tomorrow. HIV MEDICINE. vol. 15, 91-91.

Behrens G, Rijnders B, Nelson M, Orkin C, Cohen C, Mills A, Elion RA, Vanveggel S et al.(2014). Rilpivirine versus efavirenz with emtricitabine/tenofovir disoproxil fumarate in treatment-naïve HIV-1-infected patients with HIV-1 RNA ≤100,000 Copies/mL: Week 96 pooled ECHO/THRIVE subanalysis. AIDS Patient Care and STDs vol. 28, (4) 168-175.

Wilkins E, Moyle G, Orkin C, Fisher M, Johnson M, Arribas J, Van Lunzen J, Garner W et al. (2014). STaR study: Single-tablet regimen (STR) of Rilpivirine/Emtricitabine/Tenofovir DF demonstrates significant difference to Efavirenz/Emtricitabine/Tenofovir DF in subjects with a baseline HIV-1 RNA <= 100,000 copies/mL through week 96. HIV MEDICINE. vol. 15, 115-116.

Samuel M, Jose S, Winston A, Nelson M, Johnson M, Chadwick D, Fisher M, Leen C et al.(2014). The effects of age on associations between markers of HIV progression and markers of metabolic function including albumin, haemoglobin and lipid concentrations. HIV Medicine vol. 15, (5) 311-316.

Orkin C, Clumeck N, Girard P-M, Henry K, Gathe J, Rockstroh J, DeJesus E, Yau S et al. (2014). Week 144 efficacy and safety data: Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF (Stribild) demonstrates durable efficacy and differentiated safety compared to Atazanavir boosted by Ritonavir plus Emtricitabine/Tenofovir DF at week 144 in treatment-naive HIV-1-infected patients. HIV MEDICINE. vol. 15, 114-114.

O'Connor JL, Smith CJ, Lampe FC, Hill T, Gompels M, Hay P, Chadwick D, Fisher M et al.(2014). Failure to achieve a CD4⁺ cell count response on combination antiretroviral therapy despite consistent viral load suppression. AIDS vol. 28, (6) 919-924.

Coutinho R, Pria AD, Gandhi S, Bailey K, Fields P, Cwynarski K, Wilson A, Papanastasopoulos P et al.(2014). HIV status does not impair the outcome of patients diagnosed with diffuse large B-cell lymphoma treated with R-CHOP in the cART era. AIDS vol. 28, (5) 689-697.

Huntington S, Thorne C, Anderson J, Newell ML, Taylor GP, Pillay D, Hill T, Tookey P et al.(2014). Response to antiretroviral therapy (ART): Comparing women with previous use of zidovudine monotherapy (ZDVm) in pregnancy with ART naïve women. BMC Infectious Diseases vol. 14, (1)

Bower M, Palfreeman A, Alfa-Wali M, Bunker C, Burns F, Churchill D, Collins S, Cwynarski K et al.(2014). British HIV Association guidelines for HIV-associated malignancies 2014. HIV Medicine vol. 15, (S2) 1-92.

Williams I, Churchill D, Anderson J, Boffito M, Bower M, Cairns G, Cwynarski K, Edwards S et al.(2014). British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2012 (Updated November 2013. All changed text is cast in yellow highlight). HIV Medicine vol. 15, (S1) 1-6.

Wohl DA, Orkin C, Doroana M, Pilotto JH, Sungkanuparph S, Yeni P, Vanveggel S, Deckx H et al.(2014). Change in vitamin D levels and risk of severe vitamin D deficiency over 48 weeks among HIV-1-infected, treatment-naive adults receiving rilpivirine or efavirenz in a Phase III trial (ECHO). Antiviral Therapy vol. 19, (2) 191-200.

Thornhill J, Mandersloot G, Bath R, Orkin C(2014). Erratum: Opt-out HIV testing in adult critical care units (Lancet (2014) 383 (1460)). The Lancet vol. 383, (9930)

May MT, Gompels M, Delpech V, Porter K, Orkin C, Kegg S, Hay P, Johnson M et al.(2014). Impact on life expectancy of HIV-1 positive individuals of CD4R cell count and viral load response to antiretroviral therapy. AIDS vol. 28, (8) 1193-1202.

Takebe Y, Naito Y, Raghwani J, Fearnhill E, Sano T, Kusagawa S, Mbisa JL, Zhang H et al.(2014). Intercontinental dispersal of HIV-1 subtype B associated with transmission among men who have sex with men in Japan. Journal of Virology vol. 88, (17) 9864-9876.

Lodi S, Del Amo J, Moreno S, Bucher HC, Furrer H, Logan R, Sterne J, Pérez-Hoyos S et al.(2014). Opportunistic infections and AIDS malignancies early after initiating combination antiretroviral therapy in high-income countries. AIDS vol. 28, (16) 2461-2473.

Thornhill J, Mandersloot G, Bath R, Orkin C(2014). Opt-out HIV testing in adult critical care units. The Lancet vol. 383, (9927)

Geretti AM, Conibear T, Hill A, Johnson JA, Tambuyzer L, Thys K, Vingerhoets J, Van Delft Y et al.(2014). Sensitive testing of plasma HIV-1 RNA and Sanger sequencing of cellular HIV-1 DNA for the detection of drug resistance prior to starting first-line antiretroviral therapy with etravirine or efavirenz. Journal of Antimicrobial Chemotherapy vol. 69, (4) 1090-1097.

Dieterich D, Rockstroh JK, Orkin C, Gutiérrez F, Klein MB, Reynes J, Shukla U, Jenkins A et al.(2014). Simeprevir (TMC435) with pegylated interferon/ribavirin in patients coinfected with HCV Genotype 1 and HIV-1: A Phase 3 study. Clinical Infectious Diseases vol. 59, (11) 1579-1587.

Flanagan S, Crawford-Jones A, Orkin C(2014). Simeprevir for the treatment of hepatitis C and HIV/hepatitis C co-infection. Expert Review of Clinical Pharmacology vol. 7, (6) 691-704.

Rockstroh JK, Puoti M, Rodriguez-Torres M, Dieterich D, Gaggar A, Ni L, Massetto B, Svarovskaia ES et al. (2014). Sofosbuvir and Ribavirin therapy for the Treatment of HIV/HCV coinfected patients with HCV GT1-4 Infection: The PHOTON-1 and-2 Trials. HEPATOLOGY. vol. 60, 295A-296A.

Arasteh K, Drulak M, Guo J, Livrozet JM, Orkin C, Quinson AM, Ward D(2014). TRANxITION 144 week results: Switching virologically stable HIV patients from immediate-release nevirapine (NVP IR) to extended-release NVP (XR). Journal of AIDS and Clinical Research vol. 5, (4)

Orkin C, Wohl DA, Williams A, Deckx H(2014). Vitamin D deficiency in HIV: A shadow on long-term management?. AIDS Reviews vol. 16, (2) 59-74.

Molina JM, Clumeck N, Orkin C, Rimsky L, Vanveggel S, Stevens M(2014). Week 96 analysis of rilpivirine or efavirenz in HIV-1-infected patients with baseline viral load ≤100000 copies/mL in the pooled ECHO and THRIVE phase 3, randomized, double-blind trials. HIV Medicine vol. 15, (1) 57-62.

Moyle GJ, Stellbrink HJ, Compston J, Orkin C, Arribas JR, Domingo P, Granier C, Pearce H et al.(2013). 96-Week results of abacavir/lamivudine versus tenofovir/emtricitabine, plus efavirenz, in antiretroviral-naive, HIV-1-infected adults: ASSERT study. Antiviral Therapy vol. 18, (7) 905-913.

Boffito M, Fox J, Bowman C, Fisher M, Orkin C, Wilkins E, Jackson A, Pleguezuelos O et al.(2013). Safety, immunogenicity and efficacy assessment of HIV immunotherapy in a multi-centre, double-blind, randomised, Placebo-controlled Phase Ib human trial. Vaccine vol. 31, (48) 5680-5686.

Wilkins E, Nelson M, Agarwal K, Awoyemi D, Barnes E, Bhagani S, Brook G, Brown A et al.(2013). British HIV Association guidelines for the management of hepatitis viruses in adults infected with HIV 2013. HIV Medicine vol. 14, (SUPPL4) 1-71.

Castro H, Pillay D, Cane P, Asboe D, Cambiano V, Phillips A, Dunn DT, Aitken C et al.(2013). Persistence of HIV-1 transmitted drug resistance mutations. Journal of Infectious Diseases vol. 208, (9) 1459-1463.

Lodi S, Phillips A, Fidler S, Hawkins D, Gilson R, McLean K, Fisher M, Post F et al.(2013). Role of HIV Infection Duration and CD4 Cell Level at Initiation of Combination Anti-Retroviral Therapy on Risk of Failure. PLoS ONE vol. 8, (9)

Coutinho R, Flook M, Pria A, Gandhi S, Bailey K, Fields P, Cwynarski K, Wilson A et al. (2013). HIV STATUS DOES NOT INFLUENCE THE OUTCOME OF PATIENTS DIAGNOSED WITH DLBCL TREATED WITH R-CHOP IN THE HAART ERA. HAEMATOLOGICA. vol. 98, 129-129.

Winston A, Jose S, Gibbons S, Back D, Stohr W, Post F, Fisher M, Gazzard B et al.(2013). Effects of age on antiretroviral plasma drug concentration in hivinfected subjects undergoing routine therapeutic drug monitoring. Journal of Antimicrobial Chemotherapy vol. 68, (6) 1354-1359.

Waters L, Bansi L, Asboe D, Pozniak A, Smit E, Orkin C, Fearnhill E, Dunn D et al.(2013). Second-line protease inhibitor-based antiretroviral therapy after non-nucleoside reverse transcriptase inhibitor failure: The effect of a nucleoside backbone. Antiviral Therapy vol. 18, (2) 213-219.

Tariq S, Bath R, Tillett S, Nori A, Saunders J, Mandersloot G, Orkin C (2013). Opt-out HIV testing within intensive care in a large urban hospital: an innovative testing initiative. HIV MEDICINE. vol. 14, 46-46.

Orkin C, Rockstroh J, DeJesus E, Henry K, Molina J, Gathe J, Wei X, Fordyce M et al. (2013). Week 96 efficacy and safety data: Elvitegravir/cobicistat/emtricitabine/tenofovir DF (Quad) compared to atazanavir boosted by ritonavir plus emtricitabine/tenofovir DF in treatment-naive HIV-1-infected patients. HIV MEDICINE. vol. 14, 56-56.

Cohen CJ, Molina JM, Cassetti I, Chetchotisakd P, Lazzarin A, Orkin C, Rhame F, Stellbrink HJ et al.(2013). Week 96 efficacy and safety of rilpivirine in treatment-naive, HIV-1 patients in two Phase III randomized trials. AIDS vol. 27, (6) 939-950.

Brown S, Simpson DM, Moyle G, Brew BJ, Schifitto G, Larbalestier N, Orkin C, Fisher M et al.(2013). NGX-4010, a capsaicin 8% patch, for the treatment of painful HIV-associated distal sensory polyneuropathy: Integrated analysis of two phase III, randomized, controlled trials. AIDS Research and Therapy vol. 10, (1)

Orkin C, Dejesus E, Khanlou H, Stoehr A, Supparatpinyo K, Lathouwers E, Lefebvre E, Opsomer M et al.(2013). Final 192-week efficacy and safety of once-daily darunavir/ritonavir compared with lopinavir/ritonavir in HIV-1-infected treatment-naïve patients in the ARTEMIS trial. HIV Medicine vol. 14, (1) 49-59.

Winston A, Arenas-Pinto A, Stöhr W, Fisher M, Orkin CM, Aderogba K, De Burgh-Thomas A, O'Farrell N et al.(2013). Neurocognitive function in HIV infected patients on antiretroviral therapy. PLoS One vol. 8, (4)

Raffi F, Rachlis A, Stellbrink HJ, Hardy WD, Torti C, Orkin C, Bloch M, Podzamczer D et al.(2013). Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study. The Lancet vol. 381, (9868) 735-743.

Cresswell F, Gothard A, Cevik M, Haidari G, Alexander H, Katsarolis I, McGinty T, Wolujewic A et al. (2013). Safety and efficacy of rilpivirine-tenofovir-emtricitabine (Eviplera (R)) in hepatitis C-HIV coinfection. ANTIVIRAL THERAPY. vol. 18, A61-A61.

Groves KC, Bibby DF, Clark DA, Isaksen A, Deayton JR, Anderson J, Orkin C, Stagg AJ et al.(2012). Disease progression in HIV-1-infected viremic controllers. Journal of Acquired Immune Deficiency Syndromes vol. 61, (4) 407-416.

Montoto S, Shaw K, Okosun J, Gandhi S, Fields P, Wilson A, Shanyinde M, Cwynarski K et al.(2012). HIV status does not influence outcome in patients with classical Hodgkin lymphoma treated with chemotherapy using doxorubicin, bleomycin, vinblastine, and dacarbazine in the highly active antiretroviral therapy era. Journal of Clinical Oncology vol. 30, (33) 4111-4116.

Molina J-M, Clumeck N, Orkin C, Rimsky L, Vanveggel S, Stevens M (2012). Rilpivirine efficacy, virology and safety in ARV treatment-na ve patients with viral load <= 100,000 HIV-1 RNA c/mL: ECHO and THRIVE 96-week results. JOURNAL OF THE INTERNATIONAL AIDS SOCIETY. vol. 15, 150-151.

Arasteh K, Drulak M, Guo J, Livrozet J, Orkin C, Quinson A, Ward D (2012). TRANxITION 144-week results: switching virologically stable HIV patients from immediate-release nevirapine (NVP IR) to extended-release NVP (XR). JOURNAL OF THE INTERNATIONAL AIDS SOCIETY. vol. 15, 160-160.

Williams I, Churchill D, Anderson J, Boffito M, Bower M, Cairns G, Cwynarski K, Edwards S et al.(2012). British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2012. HIV medicine vol. 13, 1-85.

UK Collaborative Group on HIV Drug Resistance, Dolling D, Sabin C, Delpech V, Smit E, Pozniak A, Asboe D, Brown AL et al.(2012). Time trends in drug resistant HIV-1 infections in the United Kingdom up to 2009: multicentre observational study. BMJ vol. 345,

Nelson M, Amaya G, Clumeck N, Arns da cunha C, Jayaweera D, Junod P, Li T, Tebas P et al.(2012). Efficacy and safety of rilpivirine in treatment-naive, HIV-1-infected patients with hepatitis B virus/hepatitis C virus coinfection enrolled in the phase III randomized, double-blind ECHO and THRIVE trials. Journal of Antimicrobial Chemotherapy vol. 67, (8) 2020-2028.

Paton NI, Goodall RL, Dunn DT, Franzen S, Collaco-Moraes Y, Gazzard BG, Williams IG, Fisher MJ et al.(2012). Effects of hydroxychloroquine on immune activation and disease progression among HIV-infected patients not receiving antiretroviral therapy: A randomized controlled trial. JAMA - Journal of the American Medical Association vol. 308, (4) 353-361.

DeJesus E, Orkin C, Rockstroh J, Molina J-M, White K, Wei X, Plummer A, Kearney B et al. (2012). Efficacy, safety and pharmacokinetic results of an ongoing international phase 3 study comparing elvitegravir/cobicistat/emtricitabine/tenofovir DF (Quad) with ritonavir-boosted atazanavir plus emtricitabine/tenofovir DF in treatment naive HIV-1 infected subjects at 48 weeks. HIV MEDICINE. vol. 13, 9-9.

Barber TJ, Harrison L, Asboe D, Williams I, Kirk S, Gilson R, Bansi L, Pillay D et al.(2012). Frequency and patterns of protease gene resistance mutations in HIV-infected patients treated with lopinavir/ritonavir as their first protease inhibitor. Journal of Antimicrobial Chemotherapy vol. 67, (4) 995-1000.

Orkin C, Montoto S, Shaw K, Okosun J, Gandhi S, Fields P, Wilson A, Shanyinde M et al.(2012). HIV Status does not Impact on Outcome in Patients with Hodgkin Lymphoma Treated with ABVD Chemotherapy in the HAART Era. HIV MEDICINE vol. 13, 5-5.

Orkin C, Arribas J, Hodder S, Stellbrink HJ, Vanveggel S, Deckx H, Stevens M (2012). Incidence of rash in the 96-week analysis of the pooled Phase III randomised double-blind ECHO and THRIVE trials. HIV MEDICINE. vol. 13, 50-50.

Dhairyawan R, Lowe S, Ncube B, Jones A, Strachen S, Apea V, Orkin C (2012). The first 9 months: the lost to follow up (LTFU) clinic is born. A sustained approach to re-engaging patients. HIV MEDICINE. vol. 13, 77-77.

Arasteh K, Ward D, Plettenberg A, Livrozet JM, Orkin C, Cordes C, Guo J, Wang E et al.(2012). Twenty-four-week efficacy and safety of switching virologically suppressed HIV-1-infected patients from nevirapine immediate release 200mg twice daily to nevirapine extended release 400mg once daily (TRANxITION). HIV Medicine vol. 13, (4) 236-244.

Fätkenheuer G, Duvivier C, Rieger A, Durant J, Rey D, Schmidt W, Hill A, van Delft Y et al.(2012). Lipid profiles for etravirine versus efavirenz in treatment-naive patients in the randomized, double-blind SENSE trial. Journal of Antimicrobial Chemotherapy vol. 67, (3) 685-690.

Gompels M, Dunn DT, Phillips A, Dooley D, De Burgh Thomas A, Anderson J, Post F, Pillay D et al.(2012). Does discordancy between the CD4 count and CD4 percentage in HIV-positive individuals influence outcomes on highly active antiretroviral therapy?. Journal of Infectious Diseases vol. 205, (4) 540-547.

Dhairyawan R, Longwill S, Orkin C, Montoto S(2012). An innovative joint approach to HIV and lymphoma care. Sexually Transmitted Infections vol. 88, (1)

Asboe D, Aitken C, Boffito M, Booth C, Cane P, Fakoya A, Geretti AM, Kelleher P et al.(2012). British HIV Association guidelines for the routine investigation and monitoring of adult HIV-1-infected individuals 2011. HIV Medicine vol. 13, (1) 1-44.

Orkin C, Nelson M, Katlama C, Morlat P, Furrer H, Van Delft Y, Janssen M, Hill A et al.(2012). Changes in patient-reported neuropsychiatric outcomes during the SENSE trial: First-line treatment with two nucleoside analogues plus etravirine or efavirenz. Health Outcomes Research in Medicine vol. 3, (3)

Kober C, Johnson M, Fisher M, Hill T, Anderson J, Bansi L, Gompels M, Palfreeman A et al.(2012). Non-uptake of highly active antiretroviral therapy among patients with a CD4 count &lt;350 cells/μL in the GBR. HIV Medicine vol. 13, (1) 73-78.

Dorward J, Garrett N, Scott D, Buckland M, Orkin C, Baily G(2011). Successful treatment of acute hepatitis C virus in HIV positive patients using the European AIDS Treatment Network guidelines for treatment duration. Journal of Clinical Virology vol. 52, (4) 367-369.

Montoto S, Shaw K, Okosun J, Gandhi S, Fields P, Wilson A, Shanyinde M, Cwynarski K et al. (2011). HIV Status Does Not Impact on Outcome in Patients with Hodgkin Lymphoma Treated with ABVD Chemotherapy in the HAART Era. BLOOD. vol. 118, 1557-1557.

Hughes RA, Sterne JAC, Walsh J, Bansi L, Gilson R, Orkin C, Hill T, Ainsworth J et al.(2011). Long-term trends in CD4 cell counts and impact of viral failure in individuals starting antiretroviral therapy: UK Collaborative HIV Cohort (CHIC) study. HIV Medicine vol. 12, (10) 583-593.

May M, Gompels M, Delpech V, Porter K, Post F, Johnson M, Dunn D, Palfreeman A et al.(2011). Impact of late diagnosis and treatment on life expectancy in people with HIV-1: UK Collaborative HIV Cohort (UK CHIC) Study. BMJ (Online) vol. 343, (7829)

Barber TJ, Geretti AM, Anderson J, Schwenk A, Phillips AN, Bansi L, Gilson R, Hill T et al.(2011). Outcomes in the first year after initiation of first-line HAART among heterosexual men and women in the UK CHIC Study. Antiviral Therapy vol. 16, (6) 805-814.

Waters L, Fisher M, Anderson J, Wood C, Delpech V, Hill T, Walsh J, Orkin C et al.(2011). Authors' response to Drs Scourfield, Jackson and Nelson. HIV Medicine vol. 12, (7) 450-451.

Waters L, Fisher M, Anderson J, Wood C, Delpech V, Hill T, Walsh J, Orkin C et al.(2011). Responses to highly active antiretroviral therapy and clinical events in patients with a low CD4 cell count: Late presenters vs. late starters. HIV Medicine vol. 12, (5) 289-298.

Dorward J, Garrett N, Scott D, Buckland M, Orkin C, Baily G (2011). Successful treatment of acute hepatitis C virus in a cohort of HIV-positive patients. HIV MEDICINE. vol. 12, 43-43.

Duprez DA, Neuhaus J, Tracy R, Kuller LH, Deeks SG, Orkin C, Stoehr A, Woolley IJ et al.(2011). N-terminal-proB-type natriuretic peptide predicts cardiovascular disease events in HIV-infected patients. AIDS vol. 25, (5) 651-657.

UK Collaborative HIV Cohort (CHIC) Study Steering Committee, Garvey L, Winston A, Walsh J, Post F, Porter K, Gazzard B, Fisher M et al.(2011). HIV-associated central nervous system diseases in the recent combination antiretroviral therapy era. Eur J Neurol vol. 18, (3) 527-534.

Garvey L, Winston A, Walsh J, Post F, Porter K, Gazzard B, Fisher M, Leen C et al.(2011). Antiretroviral therapy CNS penetration and HIV-1-associated CNS disease. Neurology vol. 76, (8) 693-700.

Dreja H, O'Sullivan E, Pade C, Greene KM, Gao H, Aubin K, Hand J, Isaksen A et al.(2010). Neutralization activity in a geographically diverse East London cohort of human immunodeficiency virus type 1-infected patients: Clade C infection results in a stronger and broader humoral immune response than clade B infection. Journal of General Virology vol. 91, (11) 2794-2803.

Stellbrink HJ, Orkin C, Arribas JR, Compston J, Gerstoft J, Van Wijngaerden E, Lazzarin A, Rizzardini G et al.(2010). Comparison of changes in bone density and turnover with abacavir-lamivudine versus tenofovir-emtricitabine in HIV-infected adults: 48-week results from the ASSERT study. Clinical Infectious Diseases vol. 51, (8) 963-972.

Bansi L, Sabin C, Delpech V, Hill T, Fisher M, Walsh J, Chadborn T, Easterbrook P et al.(2010). Trends over calendar time in antiretroviral treatment success and failure in HIV clinic populations. HIV Medicine vol. 11, (7) 432-438.

Lodwick RK, Sabin CA, Porter K, Ledergerber B, Van Sighem A, Cozzi-Lepri A, Khaykin P, Mocroft A et al.(2010). Death rates in HIV-positive antiretroviral-naive patients with CD4 count greater than 350 cells per μl in Europe and North America: A pooled cohort observational study. The Lancet vol. 376, (9738) 340-345.

Orkin C, Wang J, Bergin C, Molina JM, Lazzarin A, Cavassini M, Esser S, Gómez Sirvent JL et al.(2010). An epidemiologic study to determine the prevalence of the HLA-B*5701 allele among HIV-positive patients in Europe. Pharmacogenetics and Genomics vol. 20, (5) 307-314.

Alesandro CL, Dunn D, Pillay D, Sabin CA, Fearnhill E, Gerettsabini AM, Hill T, Kaye S et al.(2010). Long-term probability of detecting drug-resistant HIV in treatment-naive patients initiating combination antiretroviral therapy. Clinical Infectious Diseases vol. 50, (9) 1275-1285.

Deayton J, Bibby D, Orkin C, O'Sullivan E, McKnight A, Clark D (2010). Inter-clade dual HIV-1 infection in the UK - an emerging phenomenon.

Montoto S, Wilson J, Shaw K, Heath M, Wilson A, McNamara C, Orkin C, Nelson M et al.(2010). Excellent immunological recovery following CODOX-M/IVAC, an effective intensive chemotherapy for HIV-associated Burkitt's lymphoma. AIDS vol. 24, (6) 851-856.

Orkin C, Sadiq ST, Rice L, Jackson F(2010). Prospective epidemiological study of the prevalence of human leukocyte antigen (HLA)-B5701 in HIV-1-infected UK subjects. HIV Medicine vol. 11, (3) 187-192.

Tavel JA, Babiker A, Carey C, Fisher M, Fox L, Gey D, Lopardo GD, Lopez JC et al.(2010). Effects of intermittent IL-2 alone or with peri-cycle antiretroviral therapy in early HIV infection: The STALWART study. PLoS ONE vol. 5, (2)

Gilson R, Man SL, Copas A, Rider A, Forsyth S, Hill T, Bansi L, Porter K et al.(2010). Discordant responses on starting highly active antiretroviral therapy: Suboptimal CD4 increases despite early viral suppression in the UK Collaborative HIV Cohort (UK CHIC) Study. HIV Medicine vol. 11, (2) 152-160.

Corti D, Langedijk JPM, Hinz A, Seaman MS, Vanzetta F, Fernandez-Rodriguez BM, Silacci C, Pinna D et al.(2010). Analysis of memory B cell responses and isolation of novel monoclonal antibodies with neutralizing breadth from HIV-1-infected individuals. PLoS ONE vol. 5, (1)

Hill T, Bansi L, Sabin C, Phillips A, Dunn D, Anderson J, Easterbrook P, Fisher M et al.(2010). Data linkage reduces loss to follow-up in an observational HIV cohort study. Journal of Clinical Epidemiology vol. 63, (10) 1101-1109.

Turner J, Bansi L, Gilson R, Gazzard B, Walsh J, Pillay D, Orkin C, Phillips A et al.(2010). The prevalence of hepatitis C virus (HCV) infection in HIV-positive individuals in the UK - Trends in HCV testing and the impact of HCV on HIV treatment outcomes. Journal of Viral Hepatitis vol. 17, (8) 569-577.

Stöhr W, Back D, Dunn D, Sabin C, Winston A, Gilson R, Pillay D, Hill T et al.(2009). Factors influencing lopinavir and atazanavir plasma concentration. Journal of Antimicrobial Chemotherapy vol. 65, (1) 129-137.

Bansi L, Turner J, Gilson R, Post F, Gazzard B, Leen C, Anderson J, Porter K et al.(2009). Is 1 alanine transaminase &gt;200 IU enough to define an alanine transaminase flare in HIV-infected populations? A new definition derived from a large cohort study. Journal of Acquired Immune Deficiency Syndromes vol. 52, (3) 391-396.

Dreja H, O'Sullivan E, Pade C, Aubin K, Isaksen A, D'Souza C, Hand J, Orkin C et al.(2009). P04-35. Neutralisation activity in a geographically diverse East London cohort of HIV-1 infected patients. Retrovirology vol. 6, (SUPPL. 3)

Groves KC, Bibby D, Isaksen A, Deayton J, Anderson J, Orkin C, Stagg AJ, McKnight T(2009). P16-21. Altered T cell homeostasis and activation in HIV-1 elite suppressors with low CD4+ T-cell counts. Retrovirology vol. 6, (SUPPL. 3)

Khachi H, O'Connell R, Ladenheim D, Orkin C(2009). Pharmacokinetic interactions between rifabutin and lopinavir/ritonavir in HIV-infected patients with mycobacterial co-infection. Journal of Antimicrobial Chemotherapy vol. 64, (4) 871-873.

Bansi L, Sabin C, Gilson R, Gazzard B, Leen C, Anderson J, Dunn D, Hill T et al.(2009). Virological response to initial antiretroviral regimens containing abacavir or tenofovir. Journal of Infectious Diseases vol. 200, (5) 710-714.

Fisher M, Moyle GJ, Shahmanesh M, Orkin C, Kingston M, Wilkins E, Ewan J, Liu H et al. (2009). A randomized comparative trial of continued zidovudine/lamivudine or replacement with tenofovir disoproxil fumarate/emtricitabine in efavirenz-treated HIV-1-infected individuals. Journal of Acquired Immune Deficiency Syndromes. vol. 51, 562-568.

Bower M, Fisher M, Hill T, Reeves I, Walsh J, Orkin C, Phillips AN, Bansi L et al.(2009). CD4 counts and the risk of systemic non-Hodgkin's lymphoma in individuals with HIV in the UK. Haematologica vol. 94, (6) 875-880.

Sabin CA, Smith CJ, Delpech V, Anderson J, Bansi L, Gilson R, Schwenk A, Leen C et al.(2009). The associations between age and the development of laboratory abnormalities and treatment discontinuation for reasons other than virological failure in the first year of highly active antiretroviral therapy. HIV Medicine vol. 10, (1) 35-43.

Montoto S, Wilson J, Shaw K, Heath M, Wilson A, Orkin C, McNamara C, Johnson M et al. (2008). Excellent Immune Recovery Following the Intensive Chemotherapy CODOX-M/IVAC, An Effective Therapy for HIV-Assochited Burkitt's Lymphorna (BL). BLOOD. vol. 112, 1235-1236.

Sabin CA, Lee KJ, Dunn D, Porter K, Bansi RGL, Hill T, Phillips AN, Schwenk A et al. (2008). Treatment switches after viral rebound in HIV-infected adults starting antiretroviral therapy: Multicentre cohort study: The United Kingdom Collaborative HIV Cohort (CHIC) Study. AIDS. vol. 22, 1943-1950.

Ladenheim D, Horn O, Werneke U, Phillpot M, Murungi A, Theobald N, Orkin C(2008). Potential health risks of complementary alternative medicines in HIV patients. HIV Medicine vol. 9, (8) 653-659.

El-Sadr WM, Grund B, Neaton JD, Neuhaus J, Cohen CJ, Darbyshire J, Babiker A, Emery S et al.(2008). Risk for opportunistic disease and death after reinitiating continuous antiretroviral therapy in patients with HIV previously receiving episodic therapy: A randomized trial. Annals of Internal Medicine vol. 149, (5) 289-299.

Stöhr W, Back D, Dunn D, Sabin C, Winston A, Gilson R, Pillay D, Hill T et al.(2008). Factors influencing efavirenz and nevirapine plasma concentration: Effect of ethnicity, weight and co-medication. Antiviral Therapy vol. 13, (5) 675-685.

Montoto S, Wilson J, Shaw K, Heath M, Wilson A, Orkin C, McNamara C, Bower M et al. (2008). CODOX-M/IVAC CHEMOTHERAPY IS AN EFFECTIVE THERAPY FOR HIV-ASSOCIATED BURKITT'S LYMPHOMA (BL). HAEMATOLOGICA. vol. 93, 393-393.

Lundgren JD, Babiker A, El-Sadr W, Emery S, Grund B, Neaton JD, Neuhaus J, Phillips AN et al.(2008). Inferior clinical outcome of the CD4⁺ cell count-guided antiretroviral treatment interruption strategy in the SMART study: Role of CD4⁺ cell counts and HIV RNA levels during follow-up. Journal of Infectious Diseases vol. 197, (8) 1145-1155.

Emery S, Neuhaus JA, Phillips AN, Babiker A, Cohen CJ, Gatell JM, Girard PM, Grund B et al.(2008). Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART Study. Journal of Infectious Diseases vol. 197, (8) 1133-1144.

Porter K, Walker S, Hill T, Anderson J, Leen C, Johnson M, Gazzard B, Walsh J et al.(2008). Changes in outcome of persons initiating highly active antiretroviral therapy at a CD4 count less than 50 cells/mm3. Journal of Acquired Immune Deficiency Syndromes vol. 47, (2) 202-205.

Anderson J, Babiker A, Delpech V, Dunn D, Easterbrook P, Fisher M, Gazzard B, Gilson R et al.(2008). Are previous treatment interruptions associated with higher viral rebound rates in patients with viral suppression?. AIDS vol. 22, (3) 349-356.

Easterbrook PJ, Phillips AN, Hill T, Matthias R, Fisher M, Gazzard B, Gilson R, Scullard G et al.(2008). Patterns and predictors of the use of different antiretroviral drug regimens at treatment initiation in the UK. HIV Medicine vol. 9, (1) 47-56.

Bower M, Powles T, Williams S, Newsom Davis T, Atkins M, Montoto S, Orkin C, Webb A et al.(2007). Brief communication: Rituximab in HIV-associated multicentric Castleman disease. Annals of Internal Medicine vol. 147, (12) 836-839.

Phillips AN, Leen C, Wilson A, Anderson J, Dunn D, Schwenk A, Orkin C, Hill T et al.(2007). Risk of extensive virological failure to the three original antiretroviral drug classes over long-term follow-up from the start of therapy in patients with HIV infection: an observational cohort study. Lancet vol. 370, (9603) 1923-1928.

Powles T, Stebbing J, Montoto S, Nelson M, Gazzard B, Orkin C, Webb A, Bower M(2007). Rituximab as retreatment for rituximab pretreated HIV-associated multicentric Castleman disease [4]. Blood vol. 110, (12) 4132-4133.

Phillips AN, Gilson R, Easterbrook P, Fisher M, Gazzard B, Johnson M, Walsh J, Leen C et al.(2007). HIV diagnosis at CD4 count above 500 cells/mm³ and progression to below 350 cells/mm³ without antiretroviral therapy. Journal of Acquired Immune Deficiency Syndromes vol. 46, (3) 275-278.

Gupta RK, Loveday C, Kalidindi U, Lechelt M, Skinner C, Orkin C(2007). Tipranavir/T20-based salvage regimens highly effective and durable against HIV-1 with evidence for genotypic predictability of response in clinical practice. International Journal of STD and AIDS vol. 18, (9) 630-632.

Phillips AN, Gazzard B, Gilson R, Easterbrook P, Johnson M, Walsh J, Leen C, Fisher M et al.(2007). Rate of AIDS diseases or death in HIV-infected antiretroviral therapy-naive individuals with high CD4 cell count. AIDS vol. 21, (13) 1717-1721.

Benzie AA, Bansi LK, Sabin CA, Portsmouth S, Hill T, Johnson M, Gilson R, Easterbrook P et al.(2007). Increased duration of viral suppression is associated with lower viral rebound rates in patients with previous treatment failures. AIDS vol. 21, (11) 1423-1430.

Burns S, Cameron S, Cane P, Chrystie I, Churchill D, Delpech V, Pillay D, Dunn D et al.(2007). Evidence of a decline in transmitted HIV-1 drug resistance in the United Kingdom. AIDS vol. 21, (8) 1035-1039.

Stöhr W, Dunn DT, Porter K, Hill T, Gazzard B, Walsh J, Gilson R, Easterbrook P et al.(2007). CD4 cell count and initiation of antiretroviral therapy: Trends in seven UK centres, 1997-2003. HIV Medicine vol. 8, (3) 135-141.

Orkin C, Stebbing J, Nelson M, Bower M, Johnson M, Mandalia S, Jones R, Moyle G et al.(2005). A randomized study comparing a three- and four-drug HAART regimen in first-line therapy (QUAD study). Journal of Antimicrobial Chemotherapy vol. 55, (2) 246-251.

Stebbing J, Nelson M, Orkin C, Mandalia S, Bower M, Pozniak A, Gazzard B(2004). A randomized trial to investigate the recycling of stavudine and didanosine with and without hydroxyurea in salvage therapy (RESTART). Journal of Antimicrobial Chemotherapy vol. 53, (3) 501-505.

Morlese JF, Orkin CM, Abbas R, Burton C, Qazi NA, Nelson MR, Imami N, Gazzard BG(2003). Plasma IL-6 as a marker of mycobacterial immune restoration disease in HIV-1 infection. AIDS vol. 17, (9) 1411-1413.